Veru Inc. (NASDAQ:VERU) Short Interest Up 14.3% in January

Veru Inc. (NASDAQ:VERU) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 14,620,000 shares, a growth of 14.3% from the January 15th total of 12,790,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is currently 5.0 days.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Veru in a research note on Thursday, January 2nd.

Veru Stock Up 3.0 %

Shares of VERU opened at $0.54 on Friday. The stock has a market capitalization of $79.24 million, a P/E ratio of -1.93 and a beta of -0.54. The firm has a fifty day simple moving average of $0.71 and a two-hundred day simple moving average of $0.76. Veru has a twelve month low of $0.40 and a twelve month high of $1.92.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%. Sell-side analysts expect that Veru will post -0.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Veru

Several institutional investors have recently added to or reduced their stakes in the company. Gladstone Institutional Advisory LLC boosted its position in Veru by 34.2% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after buying an additional 14,500 shares during the period. Weaver Consulting Group lifted its position in shares of Veru by 41.0% in the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock worth $45,000 after purchasing an additional 20,280 shares during the period. Wells Fargo & Company MN lifted its position in shares of Veru by 37.1% in the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock worth $49,000 after purchasing an additional 20,430 shares during the period. Integrated Wealth Concepts LLC lifted its position in shares of Veru by 31.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company’s stock worth $56,000 after purchasing an additional 20,500 shares during the period. Finally, Barclays PLC lifted its position in shares of Veru by 11.8% in the 4th quarter. Barclays PLC now owns 206,515 shares of the company’s stock worth $134,000 after purchasing an additional 21,738 shares during the period. Hedge funds and other institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.